Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · May 30, 2022

Keywords

ClinConnect Summary

The Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O) is a clinical trial focused on improving cancer treatment through precision medicine. This means that researchers are looking at how individual differences in DNA, lifestyle, and environment can help create more effective treatments for various types of cancer, including breast, colorectal, pancreas, kidney, prostate, ovary, head and neck cancers, as well as leukemia, lymphoma, lung cancer, melanoma, and other solid tumors. The goal of this study is to find new ways to treat cancer and improve the health outcomes for patients.

To participate in this trial, patients need to have a confirmed diagnosis of a blood or solid tumor cancer and must be able to provide specific medical data and samples, like blood or tumor biopsies, which will help researchers learn more about their cancer. There are no age or gender restrictions, and the study is currently recruiting participants. Those who join can expect to share their medical information anonymously, which will contribute to important research that could help many cancer patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy
• 2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:
• • 1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
• • 2. Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization
• • 3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.
• • 4. Participating patients must agree to share their anonymized clinical and genomic data
• Exclusion Criteria:
• • None.